A downtrend has been apparent in Veru Inc. (VERU) lately. While the stock has lost 5.2% over the past week, it could witness a trend reversal as a hammer chart pattern was formed in its last ...

Veru anticipates filing a new IND for sabizabulin to address inflammation in atherosclerotic cardiovascular disease, with Phase 2 studies using coronary CT angiography as the primary endpoint.

Oppenheimer's continued support for Veru's stock is based on these promising findings, which could have implications for the treatment's advancement and potential market impact. The firm's $5.00 ...

A downtrend has been apparent in Veru Inc. (VERU) lately with too much selling pressure. The stock has declined 9.2% over the past four weeks. However, given the fact that it is now in oversold ...